SSP concludes Neuraxpharm acquisition of Swiss-based S.T.U. GmbH - CBD brand Hemplix™
Langenfeld, Germany, 4. January 2020 Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announced the acquisition of S.T.U. GmbH (Swiss Trade Union or S.T.U.), a leading Switzerland-based developer and distributor of natural cannabidiol (CBD) consumer products. The deal enables Neuraxpharm to enter the fast-growing CBD space and to build on its business of CNS-related products, including value-adde
